VolitionRx Limited announced a public offering of 2.96 million common shares and warrants for 1.48 million shares at $1.55 each, raising approximately $4.6 million before fees. Warrants exercisable immediately could bring an additional $2.3 million if fully exercised. The offering, involving new and existing investors, is expected to close on June 9, 2026. Proceeds will support Volition's development of epigenetic blood tests for early disease detection and monitoring.
Boehringer Ingelheim's Phase III trials of survodutide, a glucagon/GLP-1 dual agonist, showed significant metabolic health improvements in people with obesity. The SYNCHRONIZE-1 trial reported up to 16.6% weight loss, 34% reduction in visceral fat, a...
US stock futures dropped on Sunday following a significant tech sector selloff on Friday that ended a two-month rally on Wall Street. The Dow Jones futures fell over 200 points, while S&P 500 and Nasdaq-100 futures also declined by 0.5%. These market...
A New York judge has temporarily halted a lawsuit seeking ownership of 39,069 dormant Bitcoin wallets holding about 3.8 million BTC, worth roughly $235 billion. The plaintiffs argue that unclaimed Bitcoin should be treated as lost property, but legal...
Ethereum's Relative Strength Index (RSI) has dropped to its lowest level ever, falling between 17 and 25, well below the oversold threshold of 30. This unprecedented weakness coincides with a 64% price drop from its August 2025 peak and exchange bala...
A recent poll with over 16,000 votes revealed that 59% of Bitcoin investors would not admit defeat even if Bitcoin's price fell to zero. Peter Schiff, a gold advocate and critic of Bitcoin, called this unwavering loyalty 'cult-like' behavior. He also...
